NTRK1 and colorectal cancer: After an initial positive response to larotrectinib, a 55-year-old woman with advanced LMNA-NTRK1 fusion-positive colorectal cancer and a 2-year-old girl with ETV6-NTRK3 fusion-positive recurrent infantile fibrosarcoma had disease progression.